Clinical Trial Detail

NCT ID NCT04141644
Title PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (Osi+Ipi)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Utah
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Osimertinib

Age Groups: adult senior

No variant requirements are available.